(Q30979491)

27 June 2017

title

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy (English)

1 reference

proliferative diabetic retinopathy

27 June 2017

0 references

1 reference

1 reference

D Hornan

1

1 reference

27 June 2017

N Edmeades

2

1 reference

27 June 2017

R Krishnan

3

1 reference

27 June 2017

J Khan

4

1 reference

27 June 2017

J Lochhead

5

1 reference

27 June 2017

publication date

12 March 2010

1 reference

27 June 2017

1 reference

27 June 2017

volume

24

1 reference

27 June 2017

issue

8

1 reference

27 June 2017

page(s)

1315-1319

1 reference

Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Bevacizumab and retinal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Use of pegaptanib in the treatment of vitreous haemorrhage in idiopathic retinal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

Natural history of vitreous hemorrhage in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

7 January 2021

Neovascular changes after pegaptanib in diabetics

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

7 January 2021

Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

7 January 2021

Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2010.14

7 January 2021

Identifiers

DOI

10.1038/EYE.2010.14

1 reference

Dimensions Publication ID

27 June 2017

1014680052

0 references

1 reference